ADVENTRX to Present at BIO-Europe Spring Conference
February 28 2007 - 5:00AM
PR Newswire (US)
SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical company
developing anticancer and antiviral therapies, announced today that
Brian M. Culley, chief business officer and senior vice president
of business development, will present a corporate overview on
Wednesday, March 7 at 11:30 am at BIO-Europe Spring 2007.
BIO-Europe Spring is a partnering conference for the biotechnology
industry that will feature one-on-one partnering meetings and
company presentations. The conference will be held March 5-7 at the
Milano Convention Centre in Milan, Italy. More information on the
conference can be found at http://www.ebdgroup.com/bes/index.htm.
About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical research and development company focused on
commercializing anticancer and antiviral therapies that improve the
performance and safety of existing treatments by addressing
significant problems, such as drug metabolism, toxicity,
bioavailability and resistance. The Company's lead product
candidate, ANX-510, or CoFactor, is in Phase III and Phase II(b)
clinical trials for the treatment of patients with metastatic
colorectal cancer, as well as a Phase II clinical trial for the
treatment of patients with advanced breast cancer. More information
can be found on the Company's web site at http://www.adventrx.com/.
Forward Looking Statement ADVENTRX cautions you that statements
included in this press release that are not a description of
historical facts are forward-looking statements that involve risks,
uncertainties, assumptions and other factors that, if they do not
materialize or prove to be accurate, could cause ADVENTRX's results
to differ materially from historical results or those expressed or
implied by such forward-looking statements. The potential risks and
uncertainties that could cause actual results to differ materially
include, but are not limited to: uncertainties inherent in the drug
development process; the timing and success of clinical trials; the
validity of research results; the receipt of necessary approvals
from the FDA and other regulatory agencies; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
public filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at http://www.sec.gov/. ADVENTRX does not
intend to update any forward-looking statement, including as set
forth in this press release, to reflect events or circumstances
arising after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Media, Amy Martini, +1-212-301-7223
for WeissComm Partners; or Investors, Ioana C. Hone,
+1-858-552-0866 for ADVENTRX Pharmaceuticals Web site:
http://www.adventrx.com/ http://www.ebdgroup.com/bes/index.htm
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024